ARTICLE | Product Development
With a combined $3B in U.S. funding, two lead mRNA vaccines enter pivotal testing for COVID-19
July 28, 2020 2:12 AM UTC
Partners Pfizer and BioNTech are now neck-and-neck with Moderna as both groups began pivotal testing Monday of their respective mRNA vaccines for COVID-19.
Moderna Inc. (NASDAQ:MRNA) received additional funding from Operation Warp Speed, via BARDA, to complete clinical development, bringing its total award to just under $1 billion. ...